- Home
- SNOA vs OGEN Comparison
SNOA vs OGEN Comparison
Compare SNOA & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNOA
- OGEN
- Stock Information
- Founded
- SNOA 1999
- OGEN 1996
- Country
- SNOA United States
- OGEN United States
- Employees
- SNOA N/A
- OGEN N/A
- Industry
- SNOA Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SNOA Health Care
- OGEN Health Care
- Exchange
- SNOA Nasdaq
- OGEN Nasdaq
- Market Cap
- SNOA 4.6M
- OGEN 4.5M
- IPO Year
- SNOA 2007
- OGEN N/A
- Fundamental
- Price
- SNOA $2.56
- OGEN $0.32
- Analyst Decision
- SNOA
- OGEN
- Analyst Count
- SNOA 0
- OGEN 0
- Target Price
- SNOA N/A
- OGEN N/A
- AVG Volume (30 Days)
- SNOA 97.7K
- OGEN 738.8K
- Earning Date
- SNOA 11-07-2024
- OGEN 11-13-2024
- Dividend Yield
- SNOA N/A
- OGEN N/A
- EPS Growth
- SNOA N/A
- OGEN N/A
- EPS
- SNOA N/A
- OGEN N/A
- Revenue
- SNOA $13,547,000.00
- OGEN N/A
- Revenue This Year
- SNOA $36.00
- OGEN N/A
- Revenue Next Year
- SNOA $25.26
- OGEN N/A
- P/E Ratio
- SNOA N/A
- OGEN N/A
- Revenue Growth
- SNOA 11.81
- OGEN N/A
- 52 Week Low
- SNOA $2.52
- OGEN $0.28
- 52 Week High
- SNOA $9.40
- OGEN $7.74
- Technical
- Relative Strength Index (RSI)
- SNOA 39.95
- OGEN 41.16
- Support Level
- SNOA $2.76
- OGEN $0.30
- Resistance Level
- SNOA $2.84
- OGEN $0.43
- Average True Range (ATR)
- SNOA 0.21
- OGEN 0.03
- MACD
- SNOA -0.01
- OGEN 0.01
- Stochastic Oscillator
- SNOA 0.01
- OGEN 23.47
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.